Tango Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNGX research report →
Range $24 – $69
Price Chart
About the company
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5).
- CEO
- Malte Peters
- IPO
- 2020
- Employees
- 137
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on TNGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.83B
- P/E
- -27.66
- Fwd P/E
- 20.60
- PEG
- -0.70
- P/S
- 71.13
- P/B
- 3.44
- EV/EBITDA
- -28.74
- Div Yield
- 0.00%
- Gross Margin
- 98.25%
- Op Margin
- -253.38%
- Net Margin
- -229.92%
- ROE
- -25.74%
- ROIC
- -12.90%
Latest fiscal year · YoY change
- Revenue
- $62.38M+48.3%
- Gross Profit
- $60.10M+42.9%
- Op Income
- $-111,289,000
- Net Income
- $-101,594,000+22.0%
- EPS
- $-0.87+26.9%
- OCF Growth
- -5.6%
- FCF Growth
- -5.8%
- 52W High
- $34.39
- 52W Low
- $6.25
- 50D MA
- $28.67
- 200D MA
- $18.66
- Beta
- 1.15
- RSI (14)
- 34
- Avg Volume
- 3.80M
No earnings-call transcripts are available for TNGX yet.
- Free Float
- 65.3%
- Shares Outstanding
- 162.81M
- Float Shares
- 106.26M
of shares held by institutions
198 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 13.90M | ▲ 600.00K |
| Blackrock, Inc. | 12.44M | ▲ 3.69M |
| Fmr LLC | 12.33M | ▲ 2.43M |
| Farallon Capital Management LLC | 12.28M | ▲ 3.18M |
| Boxer Capital Management, LLC | 10.88M | 0 |
| Goldman Sachs Group Inc | 9.98M | ▲ 4.90M |
| Tcg Crossover Management, LLC | 9.08M | ▼ 1.45M |
| Vanguard Group Inc | 6.75M | ▲ 1.70M |
| Trv Gp Iv, LLC | 6.37M | 0 |
| Paradigm Biocapital Advisors LP | 6.36M | ▲ 2.35M |
| Price T Rowe Associates Inc | 6.35M | ▲ 5.46M |
| Siren, L.L.C. | 6.18M | ▲ 522.26K |
Held by 215 ETFs
Biggest fund positions in TNGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Crystal Adam | other | 27,000 |
| Aug 3, 26 | Crystal Adam | other | 27,000 |
| Aug 3, 26 | Crystal Adam | sell | 5,267 |
| Aug 3, 26 | Crystal Adam | sell | 21,733 |
| Jul 1, 26 | Crystal Adam | other | 27,000 |
| Jul 1, 26 | Crystal Adam | other | 27,000 |
| Jul 1, 26 | Crystal Adam | sell | 19,629 |
| Jul 1, 26 | Crystal Adam | sell | 7,371 |
| Jun 19, 26 | Azelby Robert | other | 35,910 |
| Jun 19, 26 | Azelby Robert | other | 5,740 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNGX coverage
Recent articles, reports, and earnings notes.
No research on TNGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNGX report →Tango Therapeutics: Promising Early Data, But A Long Road Ahead
seekingalpha.com · Aug 16
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
zacks.com · Aug 12
Tango Therapeutics Announces Executive Chair Transition
globenewswire.com · Aug 6
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
zacks.com · Aug 3
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of “Moderate Buy” by Analysts
defenseworld.net · Aug 3
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
zacks.com · Jul 22
Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.1% – Should You Buy?
defenseworld.net · Jul 19
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
zacks.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.